Figma Shares Indicated To Open $105/$110
Investing.com -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock rose 2.4% following the announcement that an abstract on its CRB-701 clinical study has been accepted for presentation at the European Society for Medical (TASE:BLWV) Oncology (ESMO) Congress 2025.
The abstract details updated clinical data from the company’s Phase 1/2 study of CRB-701, a next-generation Nectin-4-targeting antibody-drug conjugate being tested in patients with urothelial and non-urothelial solid tumors. The poster presentation is scheduled for October 19, 2025, at the congress in Berlin, Germany.
The ongoing three-part Phase 1/2 study is evaluating CRB-701’s safety, pharmacokinetics, and efficacy in patients with advanced solid tumors that express high levels of Nectin-4. The study has completed Part A dose escalation, which tested four predetermined doses, and is currently in Part B (dose optimization) with dosing at 2.7 mg/kg and 3.6 mg/kg in head and neck squamous cell carcinoma, cervical, and metastatic urothelial carcinoma tumors.
Corbus, a clinical-stage company focused on oncology and obesity, expects to complete dose optimization and identify a recommended Phase 2 dose in the fourth quarter of 2025. The study is being conducted across sites in both the United States and Europe.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.